Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of AC-170 Ophthalmic Solution
NCT02756624Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cetirizine in allergic conjunctivitis (AC) (2 arms), sponsored by Nicox S.A. Primary endpoints: Tolerability of AC 170 0.24% at Day 22 and Number of Treatment Related Adverse Events at 12 weeks. Started Apr 2016; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02756624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756624.